Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cudc-907
1. Cudc-907
2. 1339928-25-4
3. Cudc 907
4. Cudc907
5. Pi3k/hdac Inhibitor
6. Fimepinostat [usan]
7. N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide
8. 3s9rx35s5x
9. Chembl3622533
10. N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide
11. N-hydroxy-2-[{[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino]pyrimidine-5-carboxamide
12. Pi3k/hdac Inhibitor Centn
13. Unii-3s9rx35s5x
14. 5-pyrimidinecarboxamide, N-hydroxy-2-(((2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)methylamino)-
15. 5-pyrimidinecarboxamide, N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]methylamino]-
16. N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno(3,2-d)pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide
17. Fimepinostat (usan/inn)
18. Fimepinostat [inn]
19. Fimepinostat (cudc-907)
20. Mls006010994
21. Fimepinostat [who-dd]
22. Gtpl8952
23. Schembl1284705
24. Dtxsid90712307
25. Ex-a742
26. Hms3656h04
27. Hms3673e03
28. Bcp06870
29. Bdbm50188961
30. Mfcd22420823
31. Nsc771751
32. S2759
33. Zinc73488511
34. Akos026750340
35. Ccg-269763
36. Cs-1610
37. Cudc-907 (pi3k/hdac Inhibitori)
38. Db11891
39. Nsc-771751
40. Pi3k/hdac Inhibitor Cudc-907
41. Sb16569
42. Ncgc00346692-01
43. Ncgc00346692-04
44. Ncgc00346692-11
45. Ac-30227
46. As-57131
47. Da-34958
48. Hy-13522
49. Smr004702794
50. Db-057451
51. Ft-0700168
52. Sw219871-1
53. D11319
54. J-690133
55. Q27076926
| Molecular Weight | 508.6 g/mol |
|---|---|
| Molecular Formula | C23H24N8O4S |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 508.16412245 g/mol |
| Monoisotopic Mass | 508.16412245 g/mol |
| Topological Polar Surface Area | 167 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 726 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
61
PharmaCompass offers a list of Fimepinostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fimepinostat manufacturer or Fimepinostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fimepinostat manufacturer or Fimepinostat supplier.
PharmaCompass also assists you with knowing the Fimepinostat API Price utilized in the formulation of products. Fimepinostat API Price is not always fixed or binding as the Fimepinostat Price is obtained through a variety of data sources. The Fimepinostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fimepinostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fimepinostat, including repackagers and relabelers. The FDA regulates Fimepinostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fimepinostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fimepinostat supplier is an individual or a company that provides Fimepinostat active pharmaceutical ingredient (API) or Fimepinostat finished formulations upon request. The Fimepinostat suppliers may include Fimepinostat API manufacturers, exporters, distributors and traders.
Fimepinostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fimepinostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fimepinostat GMP manufacturer or Fimepinostat GMP API supplier for your needs.
A Fimepinostat CoA (Certificate of Analysis) is a formal document that attests to Fimepinostat's compliance with Fimepinostat specifications and serves as a tool for batch-level quality control.
Fimepinostat CoA mostly includes findings from lab analyses of a specific batch. For each Fimepinostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fimepinostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Fimepinostat EP), Fimepinostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fimepinostat USP).
